Table 3. Number and frequency of hospitals and regions with each different treatment service.

Service Offered	Hospitals with service, n = 328 (%)	Regions with service, n = 16 (%)
Surgery     ◽ Mastectomy     ◽ Lumpectomy     ◽ Axillary dissection     ◽ Sentinel lymph node biopsy     ◽ Breast reconstruction	50 (15.2%) 78 (23.8%) 33 (10.1%) 10 (3.0%) 9 (2.7%)	12 (75.0%) 13 (81.3%) 9 (56.3%) 4 (25.0%) 4 (25.0%)
Hormone Therapy     ◽ Tamoxifen     ◽ Anastrozole     ◽ Letrozole     ◽ Exemestane     ◽ Fulvestrant     ◽ Fluoxymesterone     ◽ Oophorectomy     ◽ Ovarian irradiation     ◽ Medical functional ovarian suppression (Leuprolide/Goserelin)	15 (4.6%) 13 (4.0%) 6 (1.8%) 4 (1.2%) 4 (1.2%) 1 (0.3%) 9 (2.7%) 3 (0.9%) 9 (2.7%)	8 (50.0%) 7 (43.8%) 4 (25.0%) 3 (18.8%) 3 (18.8%) 1 (6.3%) 6 (37.5%) 2 (12.5%) 4 (25.0%)
Chemotherapy     ◽ Combination either CMF, FAC, AC, EC +/- Taxanes     ◽ Cyclophosphamide     ◽ 5-Fluorouracil     ◽ Methotrexate     ◽ Anthracyclines (Doxorubicin or Epirubicin)     ◽ Taxanes (Paclitaxel or Docetaxel)     ◽ Capecitabine     ◽ Gemcitabine     ◽ Platinum-based agents (Cisplatin or Carboplatin)     ◽ Vinorelbine	18 (5.5%) 18 (5.5% 16 (4.9%) 8 (2.4%) 15 (4.6%) 11 (3.4%) 10 (3.0%) 3 (0.9%) 4 (1.2%) 2 (0.6%	8 (50.0%) 8 (50.0%) 8 (50.0%) 5 (31.3%) 7 (43.8%) 6 (37.5%) 6 (37.5%) 2 (12.5%) 2 (12.5%) 1 (6.3%)
Biologic Her2 targeted therapy     ◽ Trastuzumab     ◽ Lapatinib	6 (1.8%) 2 (0.6%)	4 (25.0%) 2 (12.5%)
Radiation (Whole Breast, Chest Wall, Nodal)	3 (0.9%)	2 (12.5%)